PPBT241220C7500
- 0.00
- 0.000.00%
Purple Biotech Newsroom
Express News | HC Wainwright & Co. Reiterates Buy on Purple Biotech, Maintains $33 Price Target
Promising Interim Results Propel Purple Biotech's Buy Rating Amid Phase 2 Success and Strategic Advancements
Purple Biotech's Promising Trials and Financial Update
Purple Biotech GAAP EPS of -$0.39
Purple Biotech | 6-K: Report of foreign private issuer (related to financial reporting)
Express News | Purple Biotech Ltd: Qtrly Loss per Ads $4.57
Express News | Purple Biotech Ltd: Now Has a Cash Runway Into the Fourth Quarter of 2025
Purple Biotech 3Q Loss/Shr 39c >PPBT
Press Release: Purple Biotech Reports Third Quarter 2024 Financial Results
Purple Biotech Identifies Potential New Serum Biomarker For Its Lead Oncology Therapeutic Candidate CM24: Associated With 79% Reduction In Risk Of Death
Purple Biotech Identifies Potential New Serum Biomarker for CM24
Express News | Purple Biotech Ltd - Phase 2 Study of Cm24 in Pancreatic Cancer Expected Q4 2024 Results
Express News | Purple Biotech Identifies Potential New Serum Biomarker for Its Lead Oncology Therapeutic Candidate Cm24: Associated With 79% Reduction in Risk of Death
12 Health Care Stocks Moving In Friday's After-Market Session
Express News | Purple Biotech Shares Are Trading Lower. The Company Presented New Data Regarding Its Tri-specific Antibody Platform CAPTN-3
Purple Biotech Unveils CAPTN-3 Cancer Therapy
Purple Biotech to Present Data for Antibody Platform at EORTC-NCI-AACR
Purple Biotech Anticipates Key Clinical Milestones
Purple Biotech Regains Nasdaq Compliance
H.C. Wainwright Maintains Purple Biotech(PPBT.US) With Buy Rating, Cuts Target Price to $33